Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/79778
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma |
Author: | Vandyke, K. Chow, A. Williams, S. To, L. Zannettino, A. |
Citation: | British Journal of Haematology, 2013; 161(4):499-507 |
Publisher: | Blackwell Publishing Ltd |
Issue Date: | 2013 |
ISSN: | 0007-1048 1365-2141 |
Statement of Responsibility: | Kate Vandyke, Annie W.S. Chow, Sharon A. Williams, Luen B. To and Andrew C.W. Zannettino |
Abstract: | N-cadherin (cadherin 2, type 1, N-cadherin (neuronal); CDN2) is a homotypic adhesion molecule that is upregulated in breast, prostate and bladder cancer. Here we investigated the prognostic significance of upregulated N-cadherin expression in multiple myeloma (MM). Our results indicate that N-cadherin protein and gene expression is abnormally increased in trephine biopsies and CD38⁺⁺/CD138⁺ plasma cells from MM patients, when compared with those of normal donors. In addition, levels of circulating N-cadherin were elevated in a subset of patients with MM (n = 81; mean: 14·50 ng/ml, range: 0–146·78 ng/ml), relative to age-matched controls (n = 27; mean: 2·66 ng/ml, range: 0–5·96 ng/ml), although this did not reach statistical significance. Notably, patients with abnormally high levels of N-cadherin (>6 ng/ml) had decreased progression-free survival (P = 0·036; hazard ratio: 1·94) and overall survival (P = 0·002; hazard ratio: 3·15), when compared with patients with normal N-cadherin levels (≤6 ng/ml). Furthermore, multivariate analyses revealed that the combination of N-cadherin levels and International Staging System (ISS) was a more powerful prognostic indicator than using ISS alone. Collectively, our studies demonstrate that circulating N-cadherin levels are a viable prognostic marker for high-risk MM patients. |
Keywords: | multiple myeloma N-cadherin prognostic marker, novel therapeutic target, ISS |
Rights: | © 2013 John Wiley & Sons Ltd |
DOI: | 10.1111/bjh.12280 |
Published version: | http://dx.doi.org/10.1111/bjh.12280 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.